Objective To study the role of ubiquitin ligase FBW7 in the sensitivity of glioma to temozolomide and its mechanism in glioma cells. Methods FBW7 overexpression lentivirus was constructed. Glioma cell line U251 was divided into 4 groups: the control group, temozolomide group, FBW7 overexpression group, and FBW7 overexpression + temozolomide group. Compared with the intervention on U251 cell lines, the differences of cell inhibitory rates in 4 different groups were analyzed by using contrast microscopy and methyl thiazolyl tetrazolium (MTT) colorimetric assay after 36 h and 72 h respectively. Flow cytometry (FC) was used to determine the cell cycle and apoptosis rate. Results The survival number of U251 cells in the three treatment groups was increased compared with the control group at both 36 h and 72 h. The inhibitory rates of temozolomide group, FBW7 overexpression group, and FBW7 overexpression +temozolomide group at 36 h were (17.6±0.8) ％, (10.4±0.6) ％, (18.6±0.6) ％ respectively compared with the control group (F=67.02, P<0.01); while at 72 h, the inhibitory rates of the three treatment groups were (25.1 ±0.4) ％, (16.7 ±0.7) ％, (29.0 ±0.9) ％ respectively compared with the control group (F= 74.61, P<0.001). Moreover, FBW7 overexpression + temozolomide group presented much greater inhibitory rate than temozolomide group (P<0.01). The G2/M arrest ratio and the cell apoptotic rate at 72 h in the three treatment groups were higher than those in the control group (F=41.63, P<0.001;F=42.30, P<0.01). The increased degree of G2/M arrest ratio and the cell apoptotic rate in FBW7 overexpression + temozolomide group were more obvious compared with temozolomide group (P<0.05, P<0.01). Conclusion FBW7 could enhance the sensitivity of glioma cells to temozolomide treatment, which is associated with G 2/M arrest and the increased apoptosis rate induced by FBW7.

OBJECTIVE To explore the main factors influencing the blood concentration of duloxetine， and provide a scientific basis for the individualized use of duloxetine. METHODS Retrospective analysis was conducted on 434 inpatients with depressive disorders at the First Hospital of Hebei Medical University， who were treated with duloxetine and underwent blood concentration monitoring between January 2022 and April 2024. The study examined the impact of various factors， including gender， age， body mass index （BMI）， gene phenotypes， combined medication， drug type （original/generic）， and genotyping results of gene single nucleotide polymorphism loci， on blood concentration and the concentration-to-dose （C/D） after dose adjustment. RESULTS The blood concentration of duloxetine was 76.65 （45.57， 130.31） ng/mL， and C/D was 0.96 （0.63， 1.60） ng·d/（mL·mg）. The blood concentration of duloxetine was positively correlated with the daily dose of administration （R2＝0.253 7， P＜0.001）. Blood concentration of duloxetine in 38.94% of patients exceeded the recommended range specified in the guidelines. Gender， age， BMI， combined use of CYP2D6 enzyme inhibitors， and CYP2D6 and CYP1A2 phenotypes had significant effects on C/D of duloxetine （P＜0.05）. CONCLUSIONS The patient’s age， gender， BMI， combined medication， and genetic phenotypes are closely related to the blood concentration of duloxetine.